|
|
|
|
Vol. 62, Issue 3, 705-713, September 2002
Department of Clinical Pharmacology (D.A.A., E.D.H., P.M.Z.), Institute of Laboratory Medicine, Lund University Hospital, Lund University, Lund, Sweden; and Department of Otorhinolaryngology (M.A.), Malmö University Hospital, Lund University, Lund, Sweden
| |
Abstract |
|---|
|
|
|---|
Anandamide acts as a full vanilloid receptor agonist in many bioassay systems, but it is a weak activator of primary afferents in the airways. To address this discrepancy, we compared the effect of different vanilloid receptor agonists in isolated airways and mesenteric arteries of guinea pig using preparations containing different phenotypes of the capsaicin-sensitive sensory nerve. We found that anandamide is a powerful vasodilator of mesenteric arteries but a weak constrictor of main bronchi. These effects of anandamide are mediated by vanilloid receptors on primary afferents and do not involve cannabinoid receptors. Anandamide also contracts isolated lung strips, an effect caused by the hydrolysis of anandamide and subsequent formation of cyclooxygenase products. Although capsaicin is equally potent in bronchi and mesenteric arteries, anandamide, resiniferatoxin, and particularly olvanil are significantly less potent in bronchi. Competition experiments with the vanilloid receptor antagonist capsazepine did not provide evidence of vanilloid receptor heterogeneity. Arachidonoyl-5-methoxytryptamine (VDM13), an inhibitor of the anandamide membrane transporter, attenuates responses to olvanil and anandamide, but not capsaicin and resiniferatoxin, in mesenteric arteries. VDM13 did not affect responses to these agonists in bronchi, suggesting that the anandamide membrane transporter is absent in this phenotype of the sensory nerve. Computer simulations using an operational model of agonism were consistent, with differences in intrinsic efficacy and receptor content being responsible for the remaining differences in agonist potency between the tissues. This study describes differences between vanilloid receptor agonists regarding tissue selectivity and provides a conceptual framework for developing tissue-selective vanilloid receptor agonists devoid of bronchoconstrictor activity.
| |
Introduction |
|---|
|
|
|---|
Capsaicin,
the hot ingredient in chili peppers, activates a subpopulation of
primary sensory neurons, generally referred to as polymodal nociceptors
(Holzer, 1991
; Julius and Basbaum, 2001
). These nociceptive nerves
participate not only in afferent signaling, but also in local responses
to potentially harmful stimuli via the release of neurotransmitters
from their peripheral nerve endings (Maggi, 1991
; Holzer, 1992
). The
receptor for capsaicin, termed the vanilloid receptor (Szallasi and
Blumberg, 1999
) or TRPV1 (Montell et al., 2002
), is a heat- and
proton-gated cation channel, which was originally proposed by
Szolcsanyi and Jancso-Gabor (1975)
and later cloned by Julius and
coworkers (Caterina et al., 1997
). Both native and artificially
expressed vanilloid receptors are activated by the endogenous lipid
anandamide (Zygmunt et al., 1999
; Smart et al., 2000
). Anandamide was
originally isolated from porcine brain as the first endogenous
cannabinoid (Devane et al., 1992
), and its biosynthesis has
subsequently been demonstrated in neurons (Di Marzo et al., 1994
),
macrophages (Di Marzo et al., 1996
), and recently in lung (Calignano et
al., 2000
). In contrast to capsaicin, anandamide and the synthetic
vanilloids and analgesic agents olvanil and SDZ 249-665 do not
induce airway obstruction in vivo (Wrigglesworth et al., 1996
; Stengel
et al., 1998
; Calignano et al., 2000
; Urban et al., 2000
). Consistent
with these observations, recent studies suggest that anandamide is a
weak constrictor of isolated airways compared with capsaicin (Craib et
al., 2001
; Tucker et al., 2001
). This is somewhat surprising, because
both anandamide and olvanil are effective vanilloid receptor agonists in many other bioassay systems (Hughes et al., 1992
; Szallasi and
Blumberg, 1999
; Zygmunt et al., 1999
; Smart et al., 2000
; Ralevic
et al., 2001
).
In the present study, we examined the effects of different vanilloid
receptor agonists in guinea pig airways and mesenteric arteries. Both
of these tissues are richly innervated with capsaicin-sensitive sensory
nerves, but the neurotransmitter systems responsible for the
physiological readouts of nerve activation are different (Fujimori et
al., 1990
; Jansen et al., 1990
; Franco-Cereceda, 1991
; White et al.,
1993
; Lundberg, 1995
; Zygmunt et al., 1999
). We show that these two
phenotypes of primary sensory nerve respond differently to the
nonpungent N-acyl amines anandamide and olvanil.
| |
Materials and Methods |
|---|
|
|
|---|
Tension Recordings.
Male Dunkin-Hartley guinea pigs
(300-500 g) were killed by cervical dislocation followed by
exsanguination. Mesenteric arteries and main bronchi were removed and
divided into ring preparations, which were 1 to 2 mm long (arterial
segments) or 1 to 2 rings of cartilage wide (main bronchi). Strips of
lung (approximately 3 × 3 × 6 mm) were cut longitudinally
from parenchyma distal to the major airways. The tissue preparations
were mounted between two metal pins in organ baths (5 ml) containing
warmed (37°C) physiological salt solution of the following
composition: 119 mM NaCl, 15 mM NaHCO3, 4.6 mM
KCl, 1.2 mM NaH2PO4, 1.2 mM
MgCl2, 1.5 mM CaCl2, and
6.0 mM (+)-glucose. The physiological salt solution was continuously
bubbled with a mixture of 95% O2 and 5%
CO2, resulting in a pH of 7.4. During an
equilibration period of approximately 1 h, the preparations were
repeatedly stretched until a passive tension of approximately 2 to 4 mN
(arterial segment), 3 to 4 mN (bronchial ring), or 2 mN (parenchymal
strip) was obtained. Isometric tension was measured as described
previously (Högestätt et al., 1983
). Experiments with
vascular preparations were carried out in the presence of indomethacin
(10 µM) and
N
-nitro-L-arginine
(300 µM). Main bronchi were studied in the presence of indomethacin
(10 µM),
N
-nitro-L-arginine
(300 µM), thiorphan (10 µM), enalaprilate (10 µM), and timolol
(10 µM) to inhibit cyclooxygenase, nitric oxide synthase, neutral
endopeptidase, angiotensin-converting enzyme, and
-adrenoceptors,
respectively. The incubation time with all drugs was at least 30 min,
and each preparation was exposed to only one treatment.
10log of the agonist
concentration eliciting half-maximal responses (pEC50) was determined by nonlinear regression
(Prism 3.0; GraphPad Software Inc., San Diego, CA).
Emax refers to the maximal response achieved.
Data are expressed as mean ± S.E.M. Statistical analyses were
performed by use of the Student's t test or analysis of
variance followed by Bonferroni's post hoc test (Prism 3.0).
Statistical significance was accepted when P < 0.05.
Computer Simulations.
An operational two-step model was
created from a combination of logistic functions as described by the
operational model of agonism (Black and Leff, 1983
). According to the
original model (Black and Leff, 1983
), the first step represents the
binding of the agonist to its receptor, and the second step represents the effector system. Although the present bioassay systems are very
complex, comprising vanilloid receptor activation, neurotransmitter release, postjunctional receptor activation, and muscle contraction or
relaxation, it may still be described by a two-step model provided that
a slope coefficient is introduced in the first equation. Thus, the
first step represents binding of the agonist to the vanilloid receptor
and neural activation (eq. 1), whereas the second step represents all
subsequent events in the signal pathway (eq. 2).
|
(1) |
|
(2) |
2 analysis.
Drugs.
The following drugs were used in the course of the
study: anandamide (Cayman Chemical, Ann Arbor, MI); arachidonic acid,
carbachol, calcitonin gene-related peptide 8-37, histamine,
N
-nitro-L-arginine,
phenylephrine, phenylmethylsulfonyl fluoride, resiniferatoxin,
thiorphan, timolol, and WIN 55212-2 (Sigma Chemical, St Louis, MO);
arachidonoyl-5-methoxytryptamine (Synthelec, Lund, Sweden); capsaicin,
capsazepine, HU-210, olvanil (Tocris Cooksin Inc., Bristol, UK);
enalaprilate (Merck-Sharp & Dohme, Stockholm, Sweden); indomethacin
(Confortid; Dumex, Copenhagen, Denmark); SR 141716A, SR 48,968, SR
140,333 (SANOFI Research Center, Montpellier, France); and
U46619 (Upjohn, Kalamazoo, MI).
| |
Results |
|---|
|
|
|---|
Functional Responses to Capsaicin in Main Bronchi and Mesenteric
Arteries.
In main bronchi, capsaicin evoked
concentration-dependent contractions (Fig.
1). Substance P and neurokinin A also
contracted this preparation (Fig. 1). The calcitonin gene-related
peptide (CGRP) receptor antagonist CGRP 8-37 (3 µM) and the
selective NK1 receptor antagonist SR 140,333 (100 nM) did not inhibit
the capsaicin-induced contractions. The selective NK2 receptor
antagonist SR 48,968 (100 nM) caused a small inhibition of these
contractions and abolished them when combined with SR 140,333.
|
Functional Responses to Anandamide in Main Bronchi and Mesenteric
Arteries.
In main bronchi, anandamide (10 µM) produced small
contractions that were not significantly enhanced by
phenylmethylsulfonyl fluoride (PMSF; 100 µM), an inhibitor of fatty
acid amidohydrolase (Fig. 2). The CB1
receptor antagonist SR 141716A (300 nM) did not affect the
anandamide-induced contractions in the absence (n = 4, data
not shown) or presence of PMSF (Fig. 2). However, when segments of main
bronchi were incubated with the competitive vanilloid receptor
antagonist capsazepine (3 µM), anandamide failed to elicit any
contraction (Fig. 2). The CB1 and cannabinoid receptor subtype 2 receptor agonists HU-210 (1 µM) and WIN 55212-2 (1 µM) did not
elicit a contraction or inhibit the response to anandamide (n
= 3; Fig. 2). Furthermore, anandamide was unable to induce a
relaxation of preparations submaximally constricted with carbachol whether or not the tissue was pretreated with capsaicin (n =
2; data not shown).
|
Functional Responses to Anandamide in Strips of Lung
Parenchyma.
In strips of lung parenchyma, anandamide at a
concentration of 100 µM produced robust contractions that were
unaffected by SR141716A (300 nM) but were strongly inhibited by either
PMSF (100 µM) or indomethacin (10 µM; Fig.
3). Lower concentrations of anandamide
(
10 µM) failed to induce a contractile response. Arachidonic acid
(10 µM) also induced contractions that were inhibited by 10 µM
indomethacin (control: 84 ± 15%, n = 4; indomethacin: 18 ± 2%, n = 3). Capsaicin (10 µM), HU-210 (1 µM), and WIN 55212-2 (1 µM) did not contract lung parenchymal
strips (n = 2-3; Fig. 3).
|
Functional Responses to Vanilloid Receptor Agonists.
We
next compared the effects of anandamide with three other vanilloid
receptor agonists (capsaicin, resiniferatoxin, and olvanil) in main
bronchi and mesenteric arteries. Whereas capsaicin was equally potent
in both tissues, anandamide, resiniferatoxin, and particularly olvanil
were less effective in main bronchi than in mesenteric arteries (Fig.
4; Table 1).
Anandamide only contracted main bronchi at the highest concentration
tested (10 µM), precluding the calculation of
EC50.
|
|
Effect of the Vanilloid Receptor Antagonist Capsazepine.
To
further characterize the receptor interactions, we constructed Schild
plots for capsazepine using capsaicin and resiniferatoxin as agonists
in both main bronchi and mesenteric arteries (Fig. 5). Because the potencies of anandamide
and olvanil were very low in main bronchi, competition experiments with
these agonists could not be conducted in this tissue. All Schild plots
had slope coefficients greater than unity (Table
2). Schild plots with capsaicin and
resiniferatoxin as agonists yielded similar pA2 values in main bronchi and mesenteric arteries. The corresponding values obtained with olvanil (pA2) and anandamide
(pA2') in mesenteric arteries also did not differ
from the pA2 values obtained with capsaicin and
resiniferatoxin (Table 2).
|
|
Effect of the Anandamide Membrane Transport Inhibitor
Arachidonoyl-5-Methoxytryptamine.
A high-affinity uptake of
anandamide is present in many cell types and represents a main pathway
for the cellular uptake of fatty acid amides in neurons (Di Marzo et
al., 1994
; Beltramo et al., 1997
). Di Marzo and coworkers recently
described two selective inhibitors of this uptake mechanism (De
Petrocellis et al., 2000
; De Petrocellis et al., 2001a
). We tested the
effect of arachidonoyl-5-methoxytryptamine (VDM13), which, at a
concentration of 50 µM, abolished the anandamide uptake in HEK293
cells exposed to 3.6 µM of anandamide (De Petrocellis et al., 2001a
).
Preincubation for 5 min with VDM13 (50 µM) caused a rightward shift
of the concentration-response curve for olvanil (173-fold) and
anandamide (2.3-fold) in mesenteric arteries (Fig. 6; Table 3). VDM13 did
not affect constrictor responses to olvanil and anandamide in main
bronchi or the effects of capsaicin and resiniferatoxin in either
tissue (Table 3). Although VDM13 reduced the difference in potency
between the tissues, olvanil, anandamide, and resiniferatoxin were
still more potent in mesenteric arteries than in main bronchi.
|
|
Computer Simulations.
According to classic receptor theory,
the potency of an agonist is dependent on the amount of receptors or
the receptor reserve (Black and Leff, 1983
). Initial computer
simulations using an operational two-step model of agonism indicated
that the intrinsic efficacy of the agonist influences this
relationship. Using data from experiments performed in the presence of
VDM13 and allowing for differences in intrinsic efficacy between
agonists, this model was used to construct concentration-response
curves for the agonists (Fig. 7). The computer simulations
provided a fit that was not significantly different from the original
data (
2 analysis = 64; df = 56).
This fit was obtained with a 1.7-fold higher intrinsic efficacy
(Sm) for each agonist in mesenteric arteries
than in main bronchi, consistent with a larger number of receptors (or
receptor reserve) in the former than in the latter tissue. The
intrinsic efficacy of capsaicin was estimated to be 14-, 13-, and
11-fold larger than that of olvanil, anandamide, and resiniferatoxin,
respectively. Almost identical slope coefficients of the first system
were estimated for the arterial (0.52) and bronchial (0.49) assays,
consistent with activation of similar pathways in the two types of
neurons. A higher slope coefficient of the second system was estimated
in the former (9.9) than in the latter (6.1) assay, probably reflecting
a higher slope coefficient for CGRP (6.6) in mesenteric arteries than
for substance P (1.3) and neurokinin A (1.1) in main bronchi
(p < 0.001). This is in line with the slope
coefficient for capsaicin being larger in mesenteric arteries than in
main bronchi.
| |
Discussion |
|---|
|
|
|---|
Activation of primary sensory nerves by capsaicin in guinea pig
main bronchi and mesenteric arteries leads to opposite functional responses that are mediated by different neurotransmitter systems. In
accord with those from previous studies, our findings show that
capsaicin-induced responses are mediated by NK1 and NK2 receptors in
main bronchi (Ellis and Undem, 1994
; Girard et al., 1997
) and by CGRP
receptors in mesenteric arteries (Fujimori et al., 1990
; Zygmunt et
al., 1999
). Because vanilloid receptor-active drugs may behave
differently in these test systems, it was of interest to compare the
effects of anandamide with those of other vanilloid receptor agonists
in these tissues. Anandamide, capsaicin, resiniferatoxin, and olvanil
are all effective vasodilators of mesenteric arteries, whereas the
synthetic cannabinoid receptor agonists HU-210 and WIN 55212-2 have no
effect. Analysis of the Schild plots for capsazepine indicates that
capsaicin, resiniferatoxin, and olvanil are all acting on the same
population of vanilloid receptors. Capsazepine also inhibits the
anandamide-induced relaxation, and the pA2' value
(6.9) agrees with the pA2 values obtained with
the other vanilloid receptor ligands (6.8-7.2).
Surprisingly, olvanil and anandamide are weak agonists in main bronchi,
whereas both of these compounds are potent and full agonists in
mesenteric arteries. Although small, the responses to anandamide and
olvanil in main bronchi are mediated by vanilloid receptors because
they are abolished by capsazepine. The selective CB1 receptor
antagonist SR 141716A as well as HU-210 and WIN 55212-2 do not affect
the anandamide-induced contraction. It is therefore unlikely that
anandamide activates inhibitory cannabinoid receptors on sensory nerves
that would oppose any vanilloid receptor-mediated release of sensory
neuropeptides, as has been demonstrated in rat skin and spinal cord
(Richardson et al., 1998a
,b
). A rapid enzymatic degradation or
metabolism via FAAH or cyclooxygenase cannot explain the weak effect of
anandamide in main bronchi, because PMSF fails to significantly
increase of the anandamide response and indomethacin was present in all
experiments. Similar findings regarding the action of anandamide in
guinea pig bronchus were recently reported (Craib et al., 2001
; Tucker
et al., 2001
).
We further investigated the action of anandamide in isolated lung
strips, because it has been proposed that anandamide induces a CB1
receptor-dependent contraction in this preparation (Calignano et al.,
2000
). We also found that anandamide at a high concentration is able to
induce a contraction in lung strips, but its action does not involve
cannabinoid receptors, because the responses are unaffected by SR
141716A. Vanilloid receptors also do not play a role in the
anandamide-induced contraction, because capsazepine is unable to
prevent the response. Furthermore, we found that HU-210, WIN 55212-2, and capsaicin are all lacking contractile activity, indicating that
cannabinoid and vanilloid receptors do not mediate contraction in
strips of lung parenchyma. However, inhibitors of FAAH and
cyclooxygenase prevent the contractile response to anandamide, which is
consistent with the hydrolysis of anandamide via FAAH to arachidonic
acid and subsequent cyclooxygenase-dependent formation of
bronchoconstrictor eicosanoids. Indeed, we found that arachidonic acid
is a powerful contractile agent, acting through an
indomethacin-sensitive pathway in this preparation. Such a metabolism
of anandamide has previously been shown to underlay the biological
actions of anandamide in bovine and sheep coronary arteries and rabbit
platelets (Pratt et al., 1998
; Braud et al., 2000
; Grainger and
Boachie-Ansah, 2001
).
Vanilloid receptor heterogeneity is one factor that could explain why
anandamide, olvanil, and resiniferatoxin are weaker agonists in main
bronchi than in mesenteric arteries. Radioligand binding studies
indicate that multiple capsaicin-sensitive vanilloid receptors may
indeed exist, because capsazepine was 35- to 50-fold more potent as an
inhibitor of specific [3H]resiniferatoxin
binding in the airways than in spinal cord, dorsal root ganglion, and
urinary bladder (Szallasi et al., 1993
). As shown in the present study,
Schild plots for capsazepine using capsaicin and resiniferatoxin as
agonists yielded pA2 values that did not differ
significantly between main bronchi and mesenteric arteries. Unless
capsazepine is unable to discriminate between these subtypes of
receptors, these findings suggest that main bronchi and mesenteric
arteries are endowed with a single population of vanilloid receptors.
The slope coefficients of the Schild plots were in all cases greater
than unity, which may indicate that not only the agonists but also
capsazepine binds to its receptor in a cooperative manner (Szallasi et
al., 1999
).
A carrier-mediated uptake of anandamide by a hypothetical anandamide
membrane transporter (AMT) is considered to be essential for
termination of the biological effects of anandamide (Di Marzo et al.,
1994
; Beltramo et al., 1997
). Di Marzo and coworkers recently reported
that the effect of anandamide on vanilloid receptors in HEK293 cells
expressing TRPV1 is dependent on such an uptake mechanism (De
Petrocellis et al., 2001a
), supporting the idea that anandamide and
capsaicin reach the binding site on the vanilloid receptor from the
inside of the cell (Jung et al., 1999
; Jordt and Julius, 2002
). The
present study provides pharmacological evidence that the AMT is present
on primary afferents in blood vessels, but not in airways, and
underscores the importance of this transport system for the biological
action of fatty acid amides in native cells. Such variability in the
expression of the AMT among different phenotypes of primary sensory
nerve can help explain why anandamide and olvanil are more potent
agonists in mesenteric arteries than in main bronchi. In line with
this, the anandamide transport inhibitor AM404, which is a very potent activator of vanilloid receptors (De Petrocellis et al., 2000
; Zygmunt
et al., 2000
), is also a poor constrictor of guinea pig airways (Craib
et al., 2001
; Tucker et al., 2001
), but it is powerful as a vasodilator
of guinea pig mesenteric arteries (D. A. Andersson, E. D. Högestätt, and P. M. Zygmunt, unpublished data).
VDM13 did not affect responses to capsaicin in either tissue. This
eliminates an effect of VDM13 on the vanilloid receptor (De Petrocellis
et al., 2001a
) or on subsequent steps of the signal pathways. It is
also in line with capsaicin having a low affinity for the AMT (Melck et
al., 1999
). Our findings also raise the possibility that the biological
activity of endogenous and synthetic fatty acid amides may be altered
in conditions associated with up- or down-regulation of the AMT.
Acidosis and activation of protein kinases A and C can increase the
effect of anandamide on vanilloid receptors, which may be of relevance
in the setting of inflammation (Premkumar and Ahern, 2000
; De
Petrocellis et al., 2001b
; Olah et al., 2001
; Vellani et al., 2001
).
Whether the AMT is regulated in a similar manner remains to be
elucidated. In this context, it is interesting that nitric oxide, which
may act as a cotransmitter in primary sensory neurons (Lundberg, 1996
),
enhances the cellular uptake of anandamide (Maccarrone et al., 1998
;
Maccarrone et al., 2000
; De Petrocellis et al., 2001a
).
|
Although VDM13 substantially reduced the differences in potencies of
the agonists between the tissues, anandamide, olvanil and
resiniferatoxin were still more potent in mesenteric arteries than in
main bronchi. It is unlikely that the remaining potency differences
reflect an incomplete inhibition of the transporter, because the
concentration of VDM13 used in the present study (50 µM) completely
inhibits the accumulation of anandamide in HEK293 cells (De Petrocellis
et al., 2001a
). The intrinsic efficacy and the receptor content are
other factors determining the potency of an agonist. According to the
classic receptor theory, the potency of an agonist will decrease with a
decreasing number of receptors. However, an agonist with a low
intrinsic efficacy may still induce a full response if the amount of
receptors is large enough. Because there are some indications in the
literature that capsaicin has a larger intrinsic efficacy than olvanil
and resiniferatoxin at native vanilloid receptors (Wardle et al.,
1997
), we performed computer simulations to explore the possibility
that agonists having different intrinsic efficacies are affected to
various extents by changes in the receptor content. Allowing for
variation of these parameters, the computer simulations could
successfully predict the intriguing experimental observation that
although capsaicin was equally potent in the two tissues, the other
agonists were less effective in main bronchi than in mesenteric
arteries. These findings are also in line with the conclusion that the
agonists act on the same type of receptor in both tissues.
The present study shows that vanilloid receptor agonists may display varying degrees of tissue selectivity depending on the presence of a facilitated membrane transport mechanism and the magnitude of the receptor reserve. Accordingly, vanilloid receptor agonists, being good substrates for the AMT and having low intrinsic efficacy, will display selectivity toward tissues and bioassay systems expressing this transporter and having a large receptor reserve. Our findings help explain why airway obstruction is not uniformly observed after systemic administration of vanilloid receptor agonists and provide a conceptual framework for developing tissue-selective agonists devoid of bronchoconstrictor activity.
| |
Footnotes |
|---|
Received March 11, 2002; Accepted June 3, 2002
The Swedish Research Council, the Swedish Council for Planning and Coordination of Research, Swedish Society for Medical Research, and the Medical Faculty of Lund (ALF) supported this work. The Swedish Research Council supported P.M.Z.
Address correspondence to: Edward Högestätt, M.D., Department of Clinical Pharmacology, University Hospital, SE-221 85 Lund, Sweden. E-mail: Edward.Hogestatt{at}klinfarm.lu.se
| |
Abbreviations |
|---|
AMT, anandamide membrane transporter;
CB1, cannabinoid receptor subtype 1;
FAAH, fatty acid amidohydrolase;
NK1, neurokinin subtype 1;
NK2, neurokinin subtype 2;
PMSF, phenylmethylsulfonyl fluoride;
VDM13, arachidonoyl-5-methoxytryptamine;
TRPV1, vanilloid receptor subtype 1;
HEK, human embryonic kidney;
WIN 55.212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone;
HU-210,
8-tetrahydrocannabinol dimethylheptyl;
SR 140,333, (1-{2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)piperidin-3-yl]ethyl}-4-phenyl-1-azonia-bicyclo-[2.2.2.]octane
chloride;
SR 141716A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide
hydrochloride;
SR 48,968, (S)-N-methyl-N-[4-(4-
acetylamino-4-phenyl
piperidino)-2-(3,4-dichlorophenyl)butyl]benzamide;
U46619, 9,11-dideoxy-9
,11
-methanoepoxy prostaglandin F2
.
| |
References |
|---|
|
|
|---|
an overview.
Can J Physiol Pharmacol
73:
908-914[Medline].This article has been cited by other articles:
![]() |
Y. S. Lin, R.-L. Lin, M.-Y. Bien, C.-Y. Ho, and Y. R. Kou Sensitization of capsaicin-sensitive lung vagal afferents by anandamide in rats: role of transient receptor potential vanilloid 1 receptors J Appl Physiol, April 1, 2009; 106(4): 1142 - 1152. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. McHugh, R. S. McMaster, R. G. Pertwee, S. Roy, A. Mahadevan, R. K. Razdan, and R. A. Ross Novel Compounds That Interact with Both Leukotriene B4 Receptors and Vanilloid TRPV1 Receptors J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 955 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wahn, J. Wolf, F. Kram, S. Frantz, and J. A. Wagner The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2491 - H2496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Domenicali, J Ros, G Fernandez-Varo, P Cejudo-Martin, M Crespo, M Morales-Ruiz, A M Briones, J-M Campistol, V Arroyo, E Vila, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors Gut, April 1, 2005; 54(4): 522 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Orliac, R. Peroni, S. M Celuch, and E. Adler-Graschinsky Potentiation of Anandamide Effects in Mesenteric Beds Isolated from Endotoxemic Rats J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 179 - 184. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||